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Abstract: 
Expansion of a Pharmacist’s Role in a Pediatric Ambulatory Clinic Setting at a Large Academic 
Children’s Medical Center 
D.J. Lorimier, PharmD1, Karen Gurwitch, PharmD2, Erin McDade, PharmD, BCPS2, Mindl Messinger, 
PharmD2, Santhi Masilamani, PharmD, MBA1 
1University of Houston College of Pharmacy; 2Texas Children’s Hospital; Houston, TX 
Background: Texas Children’s Hospital (TCH) is a 658-bed pediatric hospital consisting of 45 
ambulatory care clinics that receive 21,990 patient visits per month. The TCH infusion center 
administers roughly 900 high-risk medications per month for patients seen in endocrinology, allergy 
& immunology, GI & hepatology, and pulmonary clinics. Patients are scheduled for an appointment to 
the infusion center and their medication infusion plans are entered in advance by prescribers. Upon 
the day of patient appointment, orders from infusion plans are “released” by nursing staff for 
pharmacy verification and preparation.  I would add more of a description that reveals that there is 
no real monitoring or pro-active review rather than the steps in patient appointments.  Also add a 
hint of what is to come- the need for review prior to administration.   
Objectives: The primary objectives of this study are: 1) Develop specific monitoring parameters for 
high-risk medications commonly used in the infusion center 2) Create and implement a tool to 
evaluate appropriateness of orders (laboratory monitoring, dose, duration of therapy, post-infusion 
monitoring) 3) Identify financial risk and benefit for the organization through increased pharmacy 
presence in a high-risk, high-cost ambulatory setting servicing special populations.   
Methods: This is a single institution, retrospective analysis of pediatric patients 2 to 18 years of age 
treated at Texas Children’s Hospital Outpatient Infusion Center between September 15, 2013 and 
February 7, 2014. Patients were included if they received one of the following 5 identified high-risk 
medications in the infusion center: methylprednisolone, infliximab, immune globulin, methotrexate, 
omalizumab. Exclusions included patients > 18years of age and those not receiving any of the specific 
monitoring parameters for the selected drugs were developed. Additionally, 4-day pre-screenings of 
patients scheduled for appointments from January 6, 2014 through February 7, 2014 were performed 
by a clinic pharmacist. Therapy plans entered by physicians for patients in the EHR were utilized by 
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the clinic-based pharmacist to prospectively review medications and make appropriate interventions. 
Data collection included the following parameters for high risk medications:  
 medication-specific monitoring labs 
 pre-medications 
 dosage 
 duration of therapy 
 post-infusion monitoring.  
Potential adverse drug events were collected from retrospective and prospective chart review. Data 
were collected on paper forms and results were transcribed into an electronic database. Estimated 
cost avoidance (ECA) of identified potential adverse events was quantified using methods from 
existing literature 
Results: Standard monitoring parameters for the following five drugs were developed: 
methylprednisolone, infliximab, immune globulin, methotrexate, omalizumab. Therapy plans entered 
by physicians for patients in the EHR were utilized by the clinic-based pharmacist to prospectively 
review medications and make appropriate interventions. Twenty-six interventions out of 206 total 
orders were made during a 1-month period. A retrospective review of 569 orders over a 3-month 
period revealed 55 inappropriate orders. Number of adverse drug events (ADE) found during the 1-
month prospective review broken down by ADE category: labs – 12, dosage – 2, duration – 3, adverse 
drug reaction – 3, documentation – 6. A 1-month estimated cost avoidance of $3,164 was realized, 
extrapolated to $37,968 per year. 
Conclusions: Implementation of a pharmacist performing prospective reviews of patients scheduled 
for appointment in the infusion center using developed monitoring parameters contributed to 
estimated cost avoidance for the health system. Medical and pharmacy staffs were receptive of 
pharmacist’s prospective review and were actively engaged in reviewing changes based on 
interventions Tools utilized to perform this function will be further developed for future use through 
expansion of standardized monitoring parameters for other commonly infused medications and more 
seamless communication to providers about interventions. 
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Background 
Ambulatory services provided by large healthcare systems continue to expand in scope and volume, 
as health care systems are being impacted by coverage, reimbursement and quality initiatives while 
also contributing to higher quality and lower costs1-4. Furthermore, there has been extensive 
evidence that pharmacists can have a positive impact on patient outcomes in the ambulatory clinic 
setting5. The pharmacist’s role in these clinics has involved focusing on adherence, clinical 
consultation, prospective review, and prescribing6-10. Much of the research has focused on the adult 
population and the management of chronic disease states such as heart failure, diabetes, cholesterol 
and others11. 
One publication described the methods for implementing dialysis pharmacy services, complying with 
prospective order review after initiating services through audits of patient visits, and providing 
clinical interventions by pharmacists. Over a four-month period, pharmacists documented a total of 
77 clinical interventions with a 100% acceptance rate by physicians. Of the total interventions, 11 
were therapeutic related, 49 were safety related, and 17 were compliance related. The authors 
concluded that implementing a prospective pharmacy review in a dialysis unit reiterated the positive 
impact pharmacists can have in guiding treatment regimens in patients with chronic kidney disease7.  
In the pediatric setting, research studying pharmacist’s impact in ambulatory clinics has not been as 
extensive. One study evaluated the impact of a pharmaceutical care program administered by a 
pharmacist to children with asthma. A comprehensive asthma education and monitoring program 
that includes basic asthma knowledge, symptoms and exacerbation evaluation, pharmacotherapy 
assessment including inhaler technique, and quality of life measurements was developed. All patients 
with moderate asthma scheduled for outpatient visits with their internist over a 1-year period were 
referred for pharmacist intervention. Patients (aged 7-17) with moderate asthma attending the clinic 
were allocated to the intervention (group A) or control group (group B). Intervention patients (group 
A) were educated on their disease, pharmacotherapy, self-management, and inhalation techniques. 
Group B consisted of children with their regular treatment for asthma but without pharmaceutical 
intervention. A pediatric asthma quality of life questionnaire (PAQLQ) was applied to both groups at 
0, 2, and 9 weeks to assess the quality of life, with spirometry testing being done at the beginning and 
at the completion of the 9-week study. For the individual domains of activities, emotions, and 
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symptoms there was a significant improvement in the children who received pharmaceutical care in 
comparison with those who did not receive it. The scores of group B did not change during the 9 
weeks of follow-up with no significant changes in spirometric values in either group12. 
Another study conducted by So and colleagues focused on identifying the potential roles of a clinical 
pharmacist as a provider in a pediatric nephrology and hypertension clinic. Patients ≤18 years of age 
taking at least one medication were consecutively enrolled in the study, with demographic 
information and interventions performed during the clinic visit by a clinical pharmacist being 
recorded. Three hundred and seventy-four visits made in 283 participants were evaluated. Types of 
cognitive pharmacy interventions included medication counseling, verification of current 
medications, medication adherence, amongst others. The mean (SD) number of cognitive pharmacy 
interventions per patient was 2.3 (1.0) on the first visit, with the mean (SD) number of medications 
per patient being 5.7 (4.8) and of medications counseled per visit was 4.0 (3.4). Medication 
adherence was investigated in 141 (38%) visits. Discrepancies of medications were discovered in 12 of 
the 374 visits. The authors concluded based on the results that 
pediatric cognitive pharmacy services delivered to patients in a pediatric nephrology clinic were 
feasible and improved the quality of services while also promoting better outcomes for patients13. 
Texas Children’s hospital is a 582-bed academic medical center with approximately 45 ambulatory 
clinics attached to the hospital. In 2012, the hospital averaged 21,990 ambulatory clinic visits per 
month. One of these is a nursing-run clinic that serves as an infusion center for patients to receive 
non-oncologic intravenous medications. The infusion center accommodates roughly 400 
appointments per month, with ~900 medications infused during that time. Patients seen in allergy & 
immunology, gastrointestinal, life-threatening asthma, and endocrinology clinics make appointments 
for the infusion of medications to treat chronic diseases. As the function of the infusion center is  to 
administer medications, there is a limited physician presence in the clinic. Orders for patients are 
entered by physicians in advance of the appointment via “therapy plans.” These therapy plans outline 
all aspects of the infusion center visit, from labs to be drawn, hydration parameters, dose, infusion 
duration, post-infusion monitoring, and interval of appointments. Upon the patient arriving to clinic, 
these pre-entered therapy plan orders are “released” by nursing staff, which are then verified and 
prepared in the ambulatory care pharmacy satellite. As patient-specific therapy plans are viewable by 
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all health-care staff with the exception of pharmacy, the current structure does not lend itself to a 
true prospective review of orders.  The pharmacist will not see the medication plan for the 
appointment, only the actual medication orders once they are released. As there are many other 
considerations for the safe use of high-risk medications besides right drug, right dose, and right 
durations, the pharmacist not having access to information such as pre-labs, frequency, and previous 
medical history in one place  is a barrier to care. Patients travel from long distances to receive their 
infusions, and since the orders cannot be released until they have been checked in, the patient sits in 
the infusion chair for many hours while the medication is prepared by pharmacy. This leads to a 
perceived delay in service and thus potentially impacts patient and nursing satisfaction adversely. 
Furthermore, due to the high risk nature of many of the medications, a true prospective review by a 
pharmacist that allows for examination of all aspects of the therapy plan would possibly have an 
impact on increased patient safety within the infusion center. 
The primary objectives of this study were to address this gap in patient safety by developing specific 
monitoring parameters for high-risk medications commonly used in the infusion center, creating and 
implementing a tool to evaluate appropriateness of orders (laboratory monitoring, dose, duration of 
therapy, post-infusion monitoring), and identifying financial risk and benefit for the organization 
through increased pharmacy presence in a high-risk, high-cost ambulatory setting. 
Methods 
To identify medications for which specific monitoring parameters should be developed, a year-long 
report of medications used in the infusion center was analyzed along with the presence of FDA boxed 
warnings. An interdisciplinary team including clinical pharmacy specialists, ambulatory center staff 
pharmacists, infusion center nursing coordinators, and infusion center nursing staff targeted the 
following  parameters for identified high-risk medications: labs, dose, indication, duration of therapy, 
post-infusion monitoring. Medication package inserts, TCH formulary, existing literature, and primary 
anecdotal evidece were utilized in the development of monitoring parameters for each medication. 
For the purposes of the study, five medications were chosen. 
In order to establish a standardized prospective review of patients, pre-screenings of patients one 
week prior to scheduled appointments from January 6, 2014 through February 7, 2014 were 
performed by a clinic pharmacist stationed within the infusion center.  
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With the intention of establishing a baseline for comparison of pre- and post-prospective review data, 
a retrospective chart review was performed for patients receiving any of the five identified 
medications from September 15, 2013 through December 15, 2013 to determine appropriateness of 
the order. Interventions made by the clinic pharmacist were logged and classified into the following 
categories: labs, dosage, duration, adverse drug reaction (ADR), and documentation. 
Pre- and post-prospective review data was to be analyzed in order to compare rate of 
appropriateness based on established monitoring parameters developed for specified medications. 
This information would then be used to identify estimated cost avoidance (ECA) to the health system 
based on accepted pharmacist interventions. ECA was internally developed based on published 
literature focusing on both inpatient and outpatient metrics14-15. The level of the intervention 
outcome and corresponding estimated cost avoidance is outlined in Table 1. 
Table 1: Intervention Outcome Classification 
 
 
 
 
 
Level 1 Improved Quality of Care 0 18 0 
Level 2 Avoided drug product costs 
calculated based on drug  
product savings 
0 0 
Level 3 
Avoided additional physician 
visit 
366.73 4 1,466.92 
Level 4 
Avoided additional prescription 
order 
424.33 4 1,697.32 
Level 5 Avoided emergency room visit 845.25 0 0 
Level 6 Avoided hospital admission 26,205.40 0 0 
     3,164.00 
   
Results 
A 2013 usage report run for medications administered in the infusion center revealed 9,934 
medications during the time period. Table 2 outlines the top ten medications administered based on 
usage (hydration and pre-medications were excluded from the usage report e.g. intravenous fluids, 
acetaminophen). The top five medications (methylprednisolone, infliximab, immune globulin, 
methotrexate, omalizumab) were shown to make up 60% of total doses administered within the 
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infusion center. Of those five medications, all but methylprednisolone contained an FDA boxed 
warning regarding its use. With this information at hand, the following medications were chosen to 
have specific monitoring parameters developed for their safe use within the infusion clinic: 
methylprednisolone, infliximab, immune globulin, methotrexate, omalizumab. 
Table 2: Infusion Center Medication Usage (1-year) 
Medication 
Number of doses 
administered 
Percentage of total 
number of drugs 
administered (%) 
Methylprednisolone 2583 26 
Infliximab 1842 19 
Immune Globulin 855 9 
Methotrexate 552 6 
Omalizumab 521 5 
Ondansetron 434 4 
Cosyntropin 219 2 
Epoetin Alfa 129 1 
Mesna 117 1 
Tocilizumab 70 <1 
 
The following monitoring parameters were developed for the chosen medications: 
 Methylprednisolone: baseline vitals recorded, glucose screening, indication, dose appropriate, 
infusion time, frequency of therapy 
 Infliximab: Tb screening documented, baseline vitals recorded, indication, dose appropriate 
based on indication, infusion time (>2 hours), CBC/CRP/LFTs, frequency of therapy 
 Immune globulin: baseline vitals recorded, indication, dose appropriate, infusion time, IgG 
level (date), CBC, frequency of therapy 
 Methotrexate: current antibiotic therapy pregnancy test on file, indication, dose appropriate, 
leucovorin/folate therapy, CBC/LFTs 
 Omalizumab: presence of epinephrine IM auto-injector with patient, inclusion criteria met, IgE 
level (date), indication, dose appropriate, post-infusion anaphylactic monitoring 
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The second objective of creating and implementing a tool to evaluate appropriateness of orders 
(laboratory monitoring, dose, duration of therapy, post-infusion monitoring) was accomplished by 
utilizing electronic medical records to review therapy plans entered by physicians for individual 
patients. Due to the nature of when therapy plans were entered by physicians, many therapy plans 
were not entered 7 days before the patient was scheduled for their appointment. For this reason, the 
decision was made to implement a 4-day prospective patient review in order to properly capture the 
therapy plans for patients. The clinic pharmacist reviewed therapy plans for patients scheduled for 
appointments 4 days in advance to allow proper time for interventions to be made as necessary. 
In regards to the objective of identifying financial risk and benefit for the organization through an 
increased pharmacy presence in a high-risk, high-cost ambulatory setting, the following results were 
obtained. From January 6, 2014 – February 7, 2014 there were 206 infusions of one of the five 
medications identified for monitoring. Of those, 26 were deemed to be inappropriate and resulted in 
pharmacist interventions, representing an inappropriate order rate of 12.6%. Figure 1 shows the 
number of inappropriate order based on drug and as a percentage of total orders. 
Figure 1: January Medication Infusions 
 
Retrospective review of the five medications administered during the period of September 15, 2013 – 
December 15, 2013 revealed there were 569 administrations with 55 instances of inappropriate 
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orders that would have warranted a pharmacist intervention. This represented an inappropriate 
order rate of 9.6% (Figure 2). 
Figure 2: September - December Medication Infusions 
 
Inappropriate orders identified in the month of January were classified into one of the following five 
categories: labs, dosage, duration, adverse drug reaction, documentation. Table 3 outlines the errors 
classified by type for each individual drug. 
Table 3: Classification of Inappropriate Orders 
 
Methylprednisolone Infliximab 
Immune 
Globulin 
Methotrexate Omalizumab Total 
% of 
Total 
Labs 3 2 4 0 3 12 46.2% 
Dosage 0 0 1 0 1 2 7.7% 
Duration 2 1 0 0 0 3 11.5% 
Adverse Drug 
Reaction 
0 0 0 0 3 3 11.5% 
Documentation 1 2 0 2 1 6 23.1% 
Total (%) 6 (23) 5 (19.2) 5 (19.2) 2 (7.7%) 8 (30.8) 26  
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This information was applied to an established estimated cost avoidance (ECA) tool that was 
classified into progressively more severe outcomes. Eighteen interventions made were level 1 
outcomes, which do not directly result in cost avoidance. Four interventions were classified as level 3 
outcomes, which result in the avoidance of an additional physician visit. Interventions for level 3 
outcomes involved the ordering of labs based on pertinent patient history, and documentation. There 
were four level 4 outcomes, which result in the avoidance of additional prescription orders. These 
interventions involved adverse drug reaction precautions and drug preparation. In total, results 
showed an overall estimated cost avoidance due to interventions made to be $3,164 (Table 4). 
Table 4: Estimated Cost Avoidance (ECA) by Intervention 
Outcome 
Level 
Description Estimated Cost Avoidance ($) Frequency Total ECA ($) 
Level 1 Improved Quality of Care 0 18 0 
Level 2 Avoided drug product costs 
calculated based on drug  
product savings 
0 0 
Level 3 
Avoided additional physician 
visit 
366.73 4 1,466.92 
Level 4 
Avoided additional prescription 
order 
424.33 4 1,697.32 
Level 5 Avoided emergency room visit 845.25 0 0 
Level 6 Avoided hospital admission 26,205.40 0 0 
3,164.00 
 
Discussion 
This study evaluated the impact of a pharmacist integrated into a pediatric infusion center on 
estimated cost avoidance while also outlining the steps towards implementing the tools for the 
pharmacists to utilize for prospective review of infused high-risk meds. The results showed that out of 
36 total interventions made, 18 led to avoiding an estimated cost of $3,164. Additionally, when 
comparing interventions made during the 1-month intervention period with a 3-month retrospective 
review of patient therapy plans, it was shown that the rate of inappropriate orders were shown to 
have similar rates (12.6% vs. 9.6%) of inappropriate orders. The results showed that a pharmacist’s 
interventions resulted in $3,164 of estimated cost avoidance. This monetary figure was a result of 
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eight interventions made that according to an established cost avoidance tool saved the institution as 
well as the patient money.  The other 18 interventions could not be correlated to monetary savings; 
however their presence did improve the quality of the care for the patient.  
The development of standardized monitoring parameters for the five drugs making up 60% of usage 
over one year will help to improve efficiency within the pharmacy from an order verification 
perspective. This will also help to establish a stronger relationship between pharmacy and the 
medical team, as these parameters will enable the pharmacist to feel confident in alerting physicians 
to interventions. Literature devoted to establishing a culture of safety has identified reluctance to call 
a colleague to question an order or ask for more information due to fear of disrespectful behavior as 
a barrier to safety16-17. When communication between health care team members is limited, the 
patient is often the one who suffers. 
The use of technology in the expansion of pharmacy services in the ambulatory clinic was crucial in 
this study, as therapy plans were able to be viewed by pharmacists before orders were released for 
the patient arrived for the appointment. As discussed, the therapy plans include all information and 
directives related to the patient’s scheduled visit entered by the physician. This includes information 
related to physical assessments, labs to be drawn, infusion times, dose, pre-medications, hydration, 
and post-infusion monitoring directives. While this information was available to pharmacists in the 
past, it was located in different areas of the patient electronic health record. This was a cumbersome 
and time-intensive process to locate all of this information from the pharmacist’s perspective along 
with handling other assigned duties within the pharmacy satellite. From a time management 
perspective, waiting until the order was “released” the day of the appointment was more efficient 
from the pharmacist’s perspective. Gaining access to therapy plans allows for pharmacists to have all 
pertinent information relating to the patient appointment in one place and better facilitates a true 
prospective review. 
 
Limitations to this study include a short-term intervention period, lack of well-defined cost avoidance 
tool, documentation variation, and lack of historical potential adverse drug event (pADE) data to use 
as a baseline. Future studies should focus on the development of an ambulatory care cost avoidance 
tool that can be utilized to tangibly realize the impact of services, technology, or processes. There is a 
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paucity of literature devoted to the benefit to pharmacists on safety and quality in ambulatory 
settings, particularly in the pediatric setting. With the growing emphasis being placed on transitions 
of care, literature devoted to exploring the pharmacist’s role in that transition would be welcomed.  
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